Clinical development failure
Product candidates are still in preclinical and clinical development, so outcomes are uncertain.
- Scope
- Core pipeline
- Materiality
- high
AtaiBeckley Inc.
AtaiBeckley Inc. is a U.S.-based biopharmaceutical company focused on developing psychedelic and non-psychedelic product candidates for mental health and related indications. Through its wholly owned subsidiary Nualtis, it also operates a drug-delivery business that develops and manufactures novel oral thin film products and provides contract research and manufacturing services.
−15 726,3 %
−16 142,0 %
+1 227,6 %
11.74
11.74
| % | |
|---|---|
| Clinical-stage product candidates | 0% Psychedelic and non-psychedelic compounds being developed for future commercialization. |
| Drug-delivery technology licensing | 20% Licenses of Nualtis proprietary oral thin film technologies to customers. |
| R&D services | 80% Research and development work performed for customers under service agreements. |
| Contract development and manufacturing | 0% Development and manufacturing services for oral thin film pharmaceutical products. |
The company serves pharmaceutical and biotech customers that want to use oral thin film drug-delivery technology in...
- Pharmaceutical licenseesprimary
Buy rights to Nualtis proprietary oral thin film technology for use in their products.
- R&D collaboration customersprimary
Engage Nualtis for research and development services tied to drug-delivery programs.
- Future product commercialization partnerssecondary
Potential partners that would commercialize approved product candidates if development succeeds.
- Clinical development collaboratorssecondary
Work with the company on preclinical and clinical programs for product candidates.
AtaiBeckley is headquartered in the United States, but its operating footprint is international through research,...
- •Headquartered in the United States
- •R&D tax-credit activity in Australia, Canada, and the UK
- •Clinical and development work spans multiple jurisdictions
- •International structure supports research and manufacturing
- •Geography affects tax credits and operating costs
The company’s strategy is to advance its product candidates through preclinical and clinical development and, if...
01
Advance clinical and preclinical programsmedium-term
Regulatory approval is required before core product candidates can generate product revenue.
02
Monetize Nualtis technology through services and licensesshort-term
License and R&D agreements provide current revenue while the core pipeline remains in development.
03
Preserve non-dilutive funding capacityshort-term
Development-stage operations require external capital before product commercialization.
The company faces the classic risks of a clinical-stage biopharmaceutical business: uncertain trial outcomes,...
Regulatory approval risk
No product revenue is expected until candidates receive regulatory approval, if ever.
- Scope
- Psychedelic and non-psychedelic candidates
- Materiality
- high
Customer concentration in service revenue
License and R&D revenue comes from a limited set of agreements and can fluctuate.
- Scope
- Nualtis
- Materiality
- medium
Liquidity and financing dependence
Development-stage operations require ongoing external capital before commercialization.
- Scope
- Corporate funding
- Materiality
- high
Market volatility in investments and digital assets
Fair value changes in COMPASS and Bitcoin can affect reported results and liquidity.
- Scope
- Non-operating assets
- Materiality
- medium
Revenue recognition for license and R&D agreements
Affects quarterly revenue volatility and comparability
Fair value measurement of investments and derivatives
Can create large non-operating gains or losses
Stock-based compensation
Raises operating expenses without cash outflow
Development-stage expense recognition
Keeps reported earnings negative until commercialization
: 11/08/2026